Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Alzheimer's disease progression model based on integrated biomarkers and clinical measures.

Qiu Y, Li L, Zhou TY, Lu W; Alzheimer's Disease Neuroimaging Initiative.

Acta Pharmacol Sin. 2014 Sep;35(9):1111-20. doi: 10.1038/aps.2014.57. Epub 2014 Aug 4.

2.

Biomarkers for predicting cognitive decline in those with normal cognition.

Steenland K, Zhao L, Goldstein F, Cellar J, Lah J.

J Alzheimers Dis. 2014;40(3):587-94. doi: 10.3233/JAD-2014-131343.

3.

Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.

Llano DA, Laforet G, Devanarayan V; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):73-84. doi: 10.1097/WAD.0b013e3181f5b8d8.

PMID:
20847637
4.

Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.

Velayudhan L, Proitsi P, Westman E, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Soininen H, Spenger C, Hodges A, Powell J, Lovestone S, Simmons A; dNeuroMed Consortium.

J Alzheimers Dis. 2013;33(3):755-66. doi: 10.3233/JAD-2012-121408.

PMID:
23047370
5.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

6.

The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.

Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE; Alzheimer's Disease Neuroimaging Initiative.

Brain Imaging Behav. 2012 Dec;6(4):489-501. doi: 10.1007/s11682-012-9166-3.

7.

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Samtani MN, Raghavan N, Shi Y, Novak G, Farnum M, Lobanov V, Schultz T, Yang E, DiBernardo A, Narayan VA; Alzheimer's Disease Neuroimaging Initiative.

Br J Clin Pharmacol. 2013 Jan;75(1):146-61. doi: 10.1111/j.1365-2125.2012.04308.x.

8.

Relative contributions of biomarkers in Alzheimer's disease.

Haight TJ, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative.

Ann Epidemiol. 2012 Dec;22(12):868-75. doi: 10.1016/j.annepidem.2012.09.004. Epub 2012 Oct 24.

9.

An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.

Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, Dibernardo A, Narayan V; Alzheimer’s Disease Neuroimaging Initiative.

J Clin Pharmacol. 2012 May;52(5):629-44. doi: 10.1177/0091270011405497. Epub 2011 Jun 9.

PMID:
21659625
10.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260
11.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.

Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.

PMID:
16488378
12.

Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

Yau WW, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE.

Lancet Neurol. 2015 Aug;14(8):804-813. doi: 10.1016/S1474-4422(15)00135-0. Epub 2015 Jun 29.

13.

Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, Weiner M, Mungas D; Alzheimer’s Disease Neuroimaging Initiative.

Brain Imaging Behav. 2012 Dec;6(4):502-16. doi: 10.1007/s11682-012-9186-z.

14.

Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ.

Neurology. 2007 Mar 13;68(11):828-36.

PMID:
17353470
15.

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.

Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B.

Neurology. 1997 Jun;48(6):1511-7.

PMID:
9191757
16.

Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease.

Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Greve DN, Salat DH, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 Aug;132(Pt 8):2048-57. doi: 10.1093/brain/awp123. Epub 2009 May 21.

17.

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

Irizarry MC, Webb DJ, Bains C, Barrett SJ, Lai RY, Laroche JP, Hosford D, Maher-Edwards G, Weil JG.

J Alzheimers Dis. 2008 Jul;14(3):301-11.

PMID:
18599956
18.

Morphological and Microstructural Changes of the Hippocampus in Early MCI: A Study Utilizing the Alzheimer's Disease Neuroimaging Initiative Database.

Lee P, Ryoo H, Park J, Jeong Y; Alzheimer's Disease Neuroimaging Initiative.

J Clin Neurol. 2017 Apr;13(2):144-154. doi: 10.3988/jcn.2017.13.2.144. Epub 2017 Jan 25.

19.

The dynamics of cortical and hippocampal atrophy in Alzheimer disease.

Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Aug;68(8):1040-8. doi: 10.1001/archneurol.2011.167.

20.

Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.

Sierra-Rio A, Balasa M, Olives J, Antonell A, Iranzo A, Castellví M, Bosch B, Grau-Rivera O, Fernandez-Villullas G, Rami L, Lladó A, Sánchez-Valle R, Molinuevo JL.

Neurodegener Dis. 2016;16(1-2):69-76. doi: 10.1159/000439258. Epub 2015 Nov 12.

PMID:
26560503

Supplemental Content

Support Center